Neurokinin-3 receptor antagonists

Bibliography

• MAGGIO JE: Tachykinins. Annu. Rev. Neurosci. (1988) 11:13-28. First pharmacological comprehensive review on tachykinins.
   Google Scholar
• NAKANISHI S: Mammalian tachykinin receptors. Annu.Rev. Neurosci. (1991) 14:123–136.
   PubMed Web of Science ®Google Scholar
• TATEMOTO K, LUNDBERG JM, JORNVALL H, MUTT V:Neuropeptide K Isolation, structure and biological ac-tivities of a novel brain tachykinin. Biochem. Biophys. Res. Commun. (1985) 128:947–953.
   PubMed Web of Science ®Google Scholar
• KAGE R, MCGREGOR GP, THIM L, CONLON JM: Neuropep -tide ry: A peptide isolated from rabbit intestine that is derived from y-preprotachykinin. J. Neurochem. (1988) 50:1412–1417.
   PubMed Web of Science ®Google Scholar
• MAGGI CA, PATACCHINI R, ROVERO P, GIACHETTI A: Tachykinin receptors and tachykinin receptor antago-nists. J. Auton. Pharmacol. (1993) 13:23-93. Excellent review on tachykinins and their receptors with particular emphasis on the selectiveligands andpharmacology of theNKI and, to a lesser extent, NK2 receptor types.
   Google Scholar
• MAGGIO JE, MANTYH PW, IVERSEN LL: Part 1. Historicalperspectives of tachykinins. In: The tachykinin receptors. Buck SH (Ed.), Humana Press, Totowa, NJ (1994) 1–38.
   Google Scholar
• SNIDER RM, CONSTANTINE SJW, LOWE JA etal.: A potent nonpeptide antagonist of the substance P (NK1) recep-tor. Science (1991) 251:435-437. Disclosure of the first potent and selective non-peptide NIKi receptor antagonist utilised subsequently by other research groups as a model for designing selective NK3 or non-selective neurokinin receptor antagonists.
   Google Scholar
• PEYRONEL JF, TRUCHON A, MOUTONNIER C, GARRET C: Synthesis of RP 67,580, a new potent nonpeptide sub-stance P antagonist. Bioorg. Med. Chem. Lett (1992) 2:37–40.
   Web of Science ®Google Scholar
• EMONDS-ALT X, VILAIN P, GOULAOUIC P etal.: A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. Life Sci. (1992) 50:101-106. Disclosure of SR 48,968, the first potent NK2 receptor antagonist from dichlorophenylalkylpiperidine series; a model utilised to obtain potent and selective NK3 antagonists in the same chemical class.
   Google Scholar
• MANTYH PW, VIGNA SR, MAGGIO JE: Receptor involve- ment in pathology and disease. In: The tachykinin recep-tors. Buck SH (Ed.), Humana Press, Totowa, NJ (1994) 581–610.
   Google Scholar
• MCELROY AB: Neurokinin receptor antagonists. Curr. Opin. Ther. Pat. (1993) 3:1157–1172.
   Google Scholar
• DESAI MC: Recent advances in the discovery and char-acterization of substance P antagonists. Expert Opin. Ther. Pat. (1994) 4:315–321.
   Google Scholar
• SWAIN CJ: Neurokinin receptor antagonists. Expert Opin. Ther. Pat. (1996) 6:367-378. Up to date, patent-oriented review on neurokinin receptor antago-nists with a detailed description of chemical structures and as sociated pharmaceutical companies involved in the neurokinin receptor field in years 1990–1995.
   Google Scholar
• BUELL G, SCHULZ MF, ARKINSTALL SJ et al.: Molecular characterization, expression and localization of humanneurokinin-3 receptor. FEES (1992) 299:90-95. This paper is a milestonein thecharacterisation of the hNK3 receptor and gave to researchers a powerful assay for identifying hNK3 receptor-selective antagonists; moreover, it is the first paper on the hNK3 receptor distribution.
   Google Scholar
• HALL JM, CAULFIELD MP, WATSON SP, GUARDS: Receptor subtypes or species homologues: relevance to drug discovery. Trends Pharmacol. Sci (1993) 14:376–383.
   PubMed Web of Science ®Google Scholar
• PETITET F, BEAUJOUAN J-C, SAFFROY M, TORRENS Y, GLOWINSKI J: The nonpeptide NK2 antagonist SR 48968 is also a NK3 antagonist in the guinea pig but not in the rat. Biochem. Biophys. Res. Commun. (1993) 191:180-187. First evidence for the NK3 component of SR 48,968 and species-re-lated differences of NK3 receptors (guinea-pig versus rat).
   Google Scholar
• BOYLE SJ, MANLEY S, TANG K-W etal.: Affinity of the NK2 antagonist SR 48,968 at the NK3 tachykinin and wopioid receptors. Br. J. Pharmacol (1993) 108:24P.
   Google Scholar
• SHIGEMOTO R, YOKOTA Y, TSUCHIDA K, NAKANISHI S:Cloning and expression ofa rat neuromedinK receptor cDNA. J. Biol. Chem. (1990) 265:623–628.
   PubMed Web of Science ®Google Scholar
• HUANG R-RC, CHEUNG AH, MAZINA KE, STRADER CD,FONG TM: cDNA sequence and het erologous expression of the human neurokinin-3 receptor. Biochem. Biophys. Res. Commun. (1992) 184:966–972.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI K, TANAKA A, HARA M, NAKANISHI S: Theprimary structure and gene organization of human substance P and neuromedin K receptors. Eur. j Bio-chem. (1992) 204:1025–1033.
   Google Scholar
• WU L-H, VARTANIAN MA, OXENDER DL, CHUNG F-Z: Identification of methionine 134 and alanine 146 in the second transmembrane segment of the human tachykinin NK3 receptor as residues involved in spe-cies-selective binding to SR 48,968. Biochem Biophys. Res. Commun. (1994) 198:961–966.
   PubMed Web of Science ®Google Scholar
• CHUNG F-Z, WU L-H, TIAN Y et al.: Two classes of structurally different antagonists display similar spe-cies preference for the human tachykininneurokinin-3 receptor. Mol Pharmacol. (1995) 48:711-716. Site-directed mutagenesis identification of key amino acid residues responsible for the species-selectivity of two classes of structurally unrelated, selective NK3 antagonists.
   Google Scholar
• PATACCHINI R, MAGGI CA: Tachykinin receptors and receptor subtypes. Arch. Int. Pharmacodyn. (1995) 329:161–184.
   PubMedGoogle Scholar
• NGUYEN QT, JUKIC D, CHRETIEN L et al.: Two NK3 receptor subtypes: demonstration by biological and binding assays. Neuropeptides (1994) 27:157–161.
   PubMed Web of Science ®Google Scholar
• MEDHURST AD, HAY DWP, PARSONS AA: Evidence forNK3 receptor subtypes in rabbit isolated iris sphincter muscle using the NK3 receptor antagonists SR 142801 and SR 48968. Br. J. Pharmacol (1996) 117:203P.
   PubMed Web of Science ®Google Scholar
• OTSUKA M, YOSHIOKA K: Neurotransmitter functionsof mammalian tachykinins. Physic)]. Rev. (1993) 73:229–307.
   PubMed Web of Science ®Google Scholar
• LAUFER R, GILON C, CHOREVI M, SELINGER Z: Charac-terization of a neurokinin B receptor site in rat brain using a highly selective radioligand. J. Biol. Chem. (1986) 261:10257–10263.
   PubMed Web of Science ®Google Scholar
• SAFFROY M, BEAUJOUAN J-C, TORRENS Y et al.: Localiza-tion of tachykinin binding sites (NKt, NK2,NK3 ligands) in the rat brain. Peptides (1988) 9:227–241.
   PubMed Web of Science ®Google Scholar
• DAM T-V, ESCHER E, QUIRION R: Visualization ofneurok-inin-3 receptor sites in rat brain using the highly selective ligand [311]-senktide. Brain Res. (1990) 506:175–179.
   PubMed Web of Science ®Google Scholar
• GUARD S, WATSON SP: Tachykinin receptor types: clas-sification and membrane signalling mechanisms. Neurochem. Int (1991) 18:149–165.
   PubMed Web of Science ®Google Scholar
• NORRIS SK, BODEN PR, WOODRUFF GN: Agonists selec-tive for tachykinin NK1 and NK3 receptors excite sub-populations of neurones in the rat media habenula nucleus in vitro. Eur. j Pharmacol. (1993) 234:223–228.
   PubMed Web of Science ®Google Scholar
• TATEISHI K, KISHIMOTO S, KOBAYASHI HJ, KOBUKE K, MATSUOKA Y: Distribution and localization of neurok-inin A-like immunoreactivity and neurokinin B-like immunore activity in rat peripheral tissue. Regul. Pep-tides (1990) 30:193–200.
   PubMed Web of Science ®Google Scholar
• SCHEMANN M, KAYSER H: Effects of tachykinins on myenteric nairones of the guinea-pig gastric corpus: involvement of NK3 receptors. Pflugers Arch. (1991) 419:566–571.
   PubMed Web of Science ®Google Scholar
• KIMURA S, OKADA M, SUGITA I, KANAZAWA I, MU-NEKATA E: Novel neuropeptides, neurokinins a and 13, isolated from porcine spinal cord. Proc. Jpn. Acad. A (1983) 59:101–104.
   Google Scholar
• WORMSER U, LAUFER R, HART Y et al.: Highly selectiveagonists for substance P receptor subtypes. EMBO J. (1986) 5:2805–2808.
   PubMed Web of Science ®Google Scholar
• DRAPEAU G, DORLEANS-JUSTE P, DION S et al: Selective agonists for substance P and neurokinin receptors. Neuropeptides (1987) 10:43–54.
   PubMed Web of Science ®Google Scholar
• REGOLI D, DRAPEAU G, DION S, COUTURE R: New selec-tive agonists for neurokinin receptors: Pharmacologi-cal tools for receptor characterization. Trends Pharmacol Sci. (1988) 9:290–295.
   PubMed Web of Science ®Google Scholar
• PRITCHARD MC, BODEN P: Tachykinin NK3 receptors: biology and development of selective peptide and non- peptide ligands. Drugs Fut. (1995) 20:1163-1173. First pharmacology-oriented review on NK3 receptors and ligands. Valuable source of information for certain aspects of the present review.
   Google Scholar
• MUSSAP CJ, GERAGHTY DP, BURCHER E: Tachykinin receptors: a radioligand binding perspective. j Neuro-chem. (1993) 60:1987–2009.
   PubMed Web of Science ®Google Scholar
• RENZETTI AR, BARSACCHI P, CRISCUOLI M, LUCACCHINIA: Characterization of NK3 binding site in rat and guinea-pig cortical membranes by the selective ligand rII] senktide. Neuropeptides (1991) 18:104–114.
   Google Scholar
• SADOWSKI S, HUANG R-RC, FONG TM, MARKO 0, CAS-CIERI MA: Characterization of the binding of [1251]-Rodo-histidyl, methyl-phei neurokinin B to the neurokinin-3 receptor. Neuropeptides (1993) 24:317–319.
   PubMed Web of Science ®Google Scholar
• RIOUX F, QUIRION R, LEBLANC MA, REGOLI D, ST-PIERRE S: Possible interactions between neurotensin and pro-staglandins in the isolated rat portal vein. Life Sci. (1980) 27:259–267.
   PubMed Web of Science ®Google Scholar
• MAGGI CA, PATACCHINI R, GIACHETTI A, MELI A: Tachykinin receptors in the circular muscle of the guinea-pig ileum. Br. J. Pharmacol (1990) 101:996–1000.
   PubMed Web of Science ®Google Scholar
• HALL JM, MITCHELL D, MORTON IKM: Neurokinin recep-tors in the rabbit iris sphincter characterized by novel agonist ligands. Eur. j Pharmacol. (1993) 199:9–14.
   Web of Science ®Google Scholar
• PETITET F, SAFFROY M, TORRENS Y, GLOWINSKY J, BEAU-JOUAN J-C: A new selective bioassay for tachykinin NK3 receptors based on inositol monophosphate accumula-tion in the guinea pig ileum. Eur. j Pharmacol (1993) 247:185–191.
   PubMed Web of Science ®Google Scholar
• MOCHIZUKI-ODA N, NAKAJIMA Y, NAKANISHI S, ITO S:Characterization of the substance P receptor-mediated calcium influx in cDNA transfected Chinese hamster ovary cells. J. Biol. Chem. (1994) 269:9651–9658.
   PubMed Web of Science ®Google Scholar
• OURY-DONAT F, CARAYON P, THURNEYSSEN 0 et al: Functional characterization of the non-peptide neurok- inin-3 (NK3) receptor antagonist SR 142801 on the human NK3 receptor expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. 7her. (1995) 274:148-154. Characterisation of the functional activity of SR 142,801 on NK-B-in-duced Ca2+ mobilisation in CHO cells transfected with the hNK3 receptor.
   Google Scholar
• HASHIMOTO T, UCHIDA Y, NAMINOHIRA S, SAKAI T: Tachykinin antagonist I: Specific, competitive and tis-sue-selective neurokinin B antagonists on contractile activity on smooth muscles. Jpn. j Pharmacol (1987) 45:570–573.
   PubMedGoogle Scholar
• DRAPEAU G, ROUISSI N, NANTEL F et al.: Antagonists for the neurokinin NK3 receptor evaluated in selective receptor systems. Reg& Peptides (1990) 31:125-135. Disclosure of potent and rather selective peptide NK3 receptor antagonists.
   Google Scholar
• STABLES JM, ARKINSTALL S, BERESFORD IJM etal: A novel peptidic tachykinin antagonist which is potent at NK3 receptors. Neuropeptides (1993) 24:232.
   Google Scholar
• BODEN P, EDEN JM, HODGSON J et al.: The rational development of small molecule tachykinin NK3 recep-tor selective antagonists - The utilisation of a dipeptide chemical library in drug design. Bioorg Med. Chem. Lett. (1994) 4:1679–1684.
   Web of Science ®Google Scholar
• BODEN P, EDEN JM, HODGSON J et al.: The development of a novel series of non-peptide tachykinin NK3 recep-tor selective antagonists. Bioorg. Med. Chem. Lett. (1995) 5:1773–1778.
   Web of Science ®Google Scholar
• BODEN P, EDEN JM, HODGSON J et al: Use of a dipeptide chemical library in the development of non-peptidetachykinin NK3 receptor selective antagonists. J. Med. Chem. (1996) 39:1664-1675. The use of a dipeptide library as the source of a micromolar chemical lead for the hNK3 receptor is described; subsequent optimisation led to the identification of PD 161182 with nanomolar affinity.
   Google Scholar
• EMONDS-ALT X, BICHON D, DUCOUX JP etal: SR 142,801, the first potent non-peptide antagonist of thetachykinin NK3 receptor. Life Sci. (1995) 56:PL 27–32. Disclosure of the first potent and selective non-peptide NK3 receptor antagonist.
   Google Scholar
• GIARDINA GAM, GRUGNI M, RIGOLIO R, VASSALLO M, ERHARD K, FARINA C: A reliable and efficient synthesis of SR 142801. Bioorg. Med. Chem. Lett (1996) 6:2307–2310.
   Web of Science ®Google Scholar
• NGUYEN-LE XK, NGUYEN QT, GOBEIL F et al.: Pharma- cological characterization of SR 142801: A new non-peptide antagonist of the netrokinin NK3 receptor. Pharmacology (1996) 52:283-291. Characterisation of in vitro irreversible profile of SR 142,801.
   Google Scholar
• ROCCON A, MARCHIONNI D, NISATO D: Study of SR 142801, a new potent non-peptide NK3 receptor antago-nist on cardiovascular responses in conscious guinea-pig. Br. J. Pharmacol (1996) 118:1095–1102.
   PubMed Web of Science ®Google Scholar
• GIARDINA GAM, SARAU HM, FARINA C et al: 2-Phenyl-4-quinolinecarboxamides: A novel class of potent andselective non-peptide competitive antagonists for the human neurokinin-3 receptor. J. Med. Chem. (1996) 39:2281-2284. First medicinal chemistry paper on quinoline hNK3 receptor antago-nists and in vitro profile of SB 223412.
   Google Scholar
• DESAI MC, LEFKOWITZ SL, THADEIO PF, LONGO KP, SNIDER RM: Discovery of a potent substance P antago-nist: Recognition of a key molecular determinant. J. Med. Chem. (1992) 35:4911–4913.
   PubMed Web of Science ®Google Scholar
• SEWARD EM, SWAIN CJ, MERCHANT KJ et al.: Quinuclid-ine-based NK1 antagonists I: 3-Benzyloxy-1-azabicy-clo[2. 2.2] octa ne s. Bioorg. Med. Chem. Lett. (1993) 3:1361–1366.
   Google Scholar
• GRUGNI M, FARINA C, GIARDINA GAM et al: Potent and selective non-peptide NK3 receptor antagonists based on the quinoline framework XIVth International Sympo-sium on Medicinal Chemistry. Maastricht, The Netherlands (Sep. 1996) Poster 2.15.
   Google Scholar
• GIARDINA GAM, FARINA C, FOLEY JJ et al.: SB 223412, a novel quinoline NK3 receptor antagonist with high potency, selectivity and oral activity. XIVth International Symposium on Medicinal Chemistry. Maastricht, The Nether-lands (Sep. 1996) Oral communicaton-2, Poster 2.44.
   Google Scholar
• SARAU HM, SCHMIDT DB, ELSHOURBAGY N et al: Char- acterization of NK3 antagonist activity of SR 142801 in a human NK3 receptor cellular functional assay. Peptide Receptors Symposium. Montreal, Canada (July 1996) Book abstract VIII.0.1, Poster 42.
   Google Scholar
• SARAU HM, GRISWOLD DE, FOLEY JJ et al: Pharmacology of SB 223412, a selective high affinity orally active non-peptide NK3 receptor antagonist. Peptide Receptors Symposium. Montreal, Canada (July 1996). Abstract P4.6: 69.
   Google Scholar
• HAY DWP, GIARDINA GAM, FARINA C et al.: Pharma-cological profile of SB 223412, a novel potent and selective, non-peptide NK3 receptor antagonist. 6th An-nual Meeting of the European Neuropeptide Club. Pecs, Hungary (June 1996). Oral communication.
   Google Scholar
• BURKHOLDER TP, LE T-B, MAYNARD GD et al.: Identifica-tion and chemical synthesis of MDL 105,212, a non-se-lective, non-peptide tachykinin receptor antagonist. Tachykinins '95 Symposium. Florence, Italy, (Oct. 1995). Abstract: 21.
   Google Scholar
• BURKHOLDER TP, KUDLACZ EM, LE T-B etal: Identifica-tion and chemical synthesis of MDL 105,212, anon-pep-tide tachykinin antagonist with high affinity for NKi and NK2 receptors. Bioorg. Med. Chem. Len. (1996) 6:951-956. Chemical strategy to modulate NK1/NK2 binding affinity is described.
   Google Scholar
• MYERS AC, UNDEM BJ: Flectrophysiological effects of tachykinins and capsaicin on guinea-pig bronchial parasympathetic neurones .j Physiol. (1993) 470:665–679.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: Neural control of human airways in health and disease. Am. Rev. Rap. Dis. (1986) 134:1289–1314.
   PubMed Web of Science ®Google Scholar
• FULLER RW, CONRADSON T-B, DIXON CMS, CROSSMAN DC, BARNES PJ: Sensory neuropeptide effects in human skin. Br. J. Pharmacol. (1987) 92:781–788.
   PubMed Web of Science ®Google Scholar
• COUTURE R, KEROUAC R: Plasma protein extravasation induced by mammalian tachykinins in rat skin: influ-ence of anaesthetic agents and an acetylcholine antago-nist. Br.J Pharmacol (1987) 91:265–273.
   PubMed Web of Science ®Google Scholar
• COUTURE R, BOUCHER S, PICARD P, REGOLI D: Receptor characterization of the spinal action of neurokinins on nociception: a three receptor hypothesis. Regul. Peptides (1993) 46:426–429.
   PubMedGoogle Scholar
• MCCARSON KE, KRAUSE J: NK1 and NK3 type tachykinin receptor mRNA expression in the rat spinal cord dorsal horn is increased during adjuvant or formalin-induced nociception. j NeuroscL (1994) 14:712–720.
   PubMed Web of Science ®Google Scholar
• ARENAS E, ALBERCH J, PEREZ-NAVARRO E, SOLSONA C, MARSAL J: Neurokinin receptors differentially mediate endogenous acetylcholine release evoked by tachykin-ins in the neostriatum. I NeuroscL (1991) 11:2332–2338.
   PubMed Web of Science ®Google Scholar
• ALONSO R, FOURNIER M, CARAYON P et al: Evidence formodulation of dopamine-neuronal function by tachykinin NK3 receptor stimulation in gerbil me-sencephalic cell cultures. Eur. j NeuroscL (1996) 8:801–808.
   PubMedGoogle Scholar
• STOESSL AJ, POLANSKI E, FRYDRYSZAK H: Effects of ageing on tachykinin function in the basal ganglia. Brain Res. (1993) 632:21–28.
   PubMed Web of Science ®Google Scholar
• STOESSL AJ, DOURISH CT, IVERSEN SD: The NK3 tachykinin receptor agonist senktide elicits 5-HT-medi- ated behaviour following central or peripheral admini-stration in mice and rats. Br. J. Pharmacol. (1988) 94:285–287.
   PubMed Web of Science ®Google Scholar
• STOESSL AJ, DOURISH CT, IVERSEN SD: Pharmacologicalcharacterization of the behavioural syndrome induced by the NK3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT. Brain Res. (1990) 517:111–116.
   PubMed Web of Science ®Google Scholar
• DONALDSON LF, HASKELL CA, HANLEY MR: Functionalcharacterization by heterologous expression of a novel cloned tachykinin peptide receptor. Biochem. J. (1996) 320:1–5.
   PubMed Web of Science ®Google Scholar